Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Renal Cell 13Melanoma 7Neoplasms 3Sarcoma, Kaposi 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Leukemia 2Kidney Neoplasms 2Hematologic Neoplasms 2HIV Infections 2Brain Neoplasms 2Acquired Immunodeficiency Syndrome 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Osteosarcoma 1Myeloproliferative Disorders 1Mycosis Fungoides 1Margins of Excision 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Hodgkin Disease 1

Interventions

Rituximab 130Cyclophosphamide 113Peripheral Blood Stem Cell Transplantation 59fludarabine phosphate 55Etoposide 47Mycophenolic Acid 44Radiotherapy 41Filgrastim 41Tacrolimus 40Whole-Body Irradiation 36Busulfan 34Melphalan 33Cyclosporine 30Cytarabine 29Methotrexate 28sargramostim 27Vincristine 27Antilymphocyte Serum 27Prednisone 26Lenalidomide 23obinutuzumab 22Doxorubicin 22Carmustine 21Bortezomib 20Methylprednisolone 19fludarabine 17Dexamethasone 17Bendamustine Hydrochloride 17ibritumomab tiuxetan 15Cord Blood Stem Cell Transplantation 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Follicular × Interferon alpha-2 × Clear all
NCT00015912 2013-01-25

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡